Joe Pangenis

“So first, for 289, curious if you could provide at least, you know, for today, it could change tomorrow, but any broad strokes about your, you know, views of a pivotal study design?”

“Welcome to the next session of H.C. Wainwright's Annual Inflammation and Skin Disease Conference. My name is Joe Pangenis, Managing Director and Senior Research Analyst here at the firm.”

“So I know I might not be able to give color here ahead of the type A, but I'm going to ask anyway. Obviously, the reasons, you know, for your discussions, as Anurag said, were the clinical pharmacology and the analytical batches.”

“Right now, the guidance is, you know, moving enrollment continuing into 2026. When do you anticipate providing more visibility as to sites, enrollment numbers, and what levels of clarity can we get, do you think, starting in 26?”

“So, first on Vyjavec, Chris, you talked about one topic. I know it might be too early and also might include a lot of patient variability, so I don't know if it really could be answered.”